BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tavares LC, Marcatto LR, Santos PCJL. Genotype-guided warfarin therapy: current status. Pharmacogenomics 2018;19:667-85. [PMID: 29701078 DOI: 10.2217/pgs-2017-0207] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Vermehren C, Søgaard Nielsen R, Jørgensen S, Drastrup AM, Westergaard N. Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing. J Pers Med 2020;10:E78. [PMID: 32752034 DOI: 10.3390/jpm10030078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Xiong H, Liu T, Xiao J, Wan J, Yang J, Huang G, Han Y, Liu G, Dong X. Warfarin-induced Stevens-Johnson syndrome with severe liver injury. J Int Med Res 2021;49:3000605211033196. [PMID: 34311601 DOI: 10.1177/03000605211033196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 de Oliveira Magalhães Mourão A, Braga Gomes K, Afonso Reis E, Pedra de Souza R, de Freitas Campos EI, Dias Ribeiro D, da Costa Rocha MO, Parreiras Martins MA. Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. Pharmacogenomics J 2020;20:104-13. [PMID: 31395958 DOI: 10.1038/s41397-019-0091-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Al-Eitan LN, Elsaqa BZ, Almasri AY, Aman HA, Khasawneh RH, Alghamdi MA. Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease. Pharmgenomics Pers Med 2020;13:619-32. [PMID: 33235484 DOI: 10.2147/PGPM.S274246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Marcath LA, Pasternak AL, Hertz DL. Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. Pharmacogenomics J 2019;19:501-15. [DOI: 10.1038/s41397-019-0105-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
6 Marcatto L, Boer B, Sacilotto L, Olivetti N, Darrieux FCC, Scanavacca MI, Pereira AC, Santos PCJL. Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range. J Thromb Thrombolysis 2021;51:1043-9. [PMID: 32974757 DOI: 10.1007/s11239-020-02280-8] [Reference Citation Analysis]
7 Marcatto LR, Sacilotto L, Tavares LC, Souza DSP, Olivetti N, Strunz CMC, Darrieux FCC, Scanavacca MI, Krieger JE, Pereira AC, Santos PCJL. Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy. Front Pharmacol 2020;11:1056. [PMID: 32765269 DOI: 10.3389/fphar.2020.01056] [Reference Citation Analysis]
8 Chen X, Liu Y, Furukawa N, Jin DY, Paul Savage G, Stafford DW, Suhara Y, Williams CM, Tie JK. A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase. J Thromb Haemost 2021;19:689-700. [PMID: 33314621 DOI: 10.1111/jth.15209] [Reference Citation Analysis]
9 Alghamdi MA, Al-Eitan L, Alkhatib R, Al-Assi A, Almasri A, Aljamal H, Aman H, Khasawneh R. Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease. Int J Gen Med 2021;14:1093-100. [PMID: 33790638 DOI: 10.2147/IJGM.S298597] [Reference Citation Analysis]
10 Ajam T, Cumpian TL, Tilkens BL, Jahangir IA, Frost J, Ceretto C, Jahangir A. Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. Expert Rev Clin Pharmacol 2020;13:1309-27. [PMID: 33107345 DOI: 10.1080/17512433.2020.1842191] [Reference Citation Analysis]
11 Moraes JC, Nunes FDD, Coeli-Lacchini FB, Miyazaki AHL, Flória-Santos M, Lacchini R. Nurse empowerment through Pharmacogenetics. Rev Lat Am Enfermagem 2020;28:e3265. [PMID: 32813781 DOI: 10.1590/1518-8345.3415.3265] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zhu Y, Xu C, Liu J. Randomized controlled trial of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation. J Clin Pharm Ther 2020;45:1466-73. [PMID: 32710457 DOI: 10.1111/jcpt.13218] [Reference Citation Analysis]
13 Tavares LC, Duarte NE, Marcatto LR, Soares RAG, Krieger JE, Pereira AC, Santos PCJL. Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population. Eur J Clin Pharmacol 2018;74:1555-66. [PMID: 30051215 DOI: 10.1007/s00228-018-2528-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 de Lara DV, de Melo DO, Araújo Silva LC, Gonçalves TS, Júnior Lima Santos PC. Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews. Pharmacogenomics 2022. [PMID: 35380455 DOI: 10.2217/pgs-2021-0158] [Reference Citation Analysis]
15 Marcatto LR, Sacilotto L, Tavares LC, Facin M, Olivetti N, Strunz CMC, Darrieux FCC, Scanavacca MI, Krieger JE, Pereira AC, Santos PCJL. Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin. Front Pharmacol 2018;9:1052. [PMID: 30298004 DOI: 10.3389/fphar.2018.01052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 He S, Wu Y, Yan S, Liu J, Zhao L, Xie H, Ge S, Ye H. Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients. PeerJ 2021;9:e11549. [PMID: 34221714 DOI: 10.7717/peerj.11549] [Reference Citation Analysis]
17 Colet C, Botton MR, Schwambach KH, Amador TA, Heineck I. Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil. J Vasc Bras 2021;20:e20200214. [PMID: 34104133 DOI: 10.1590/1677-5449.200214] [Reference Citation Analysis]
18 Zhao L, Wang J, Shi S, Wu Y, Liu J, He S, Zou Y, Xie H, Ge S, Ye H. Plasma miRNA profiles associated with stable warfarin dosage in Chinese patients. PeerJ 2020;8:e9995. [PMID: 33083118 DOI: 10.7717/peerj.9995] [Reference Citation Analysis]
19 Lin X, Chen H, Ni L, Yu Y, Luo Z, Liao L. Effects of EPHX1 rs2260863 polymorphisms on warfarin maintenance dose in very elderly, frail Han-Chinese population. Pharmacogenomics 2020;21:863-70. [PMID: 32559398 DOI: 10.2217/pgs-2020-0054] [Reference Citation Analysis]
20 Hirata TDC, Dagli-Hernandez C, Genvigir FDV, Lauschke VM, Zhou Y, Hirata MH, Hirata RDC. Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. Mol Diagn Ther 2021. [PMID: 34357562 DOI: 10.1007/s40291-021-00549-z] [Reference Citation Analysis]
21 Wang D, Dai DP, Wu H, Chong J, Lü Y, Yin R, Zhao X, Zhao A, Yang J, Chen H. Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation. Pharmacogenomics 2020;21:1021-31. [PMID: 32893731 DOI: 10.2217/pgs-2020-0051] [Reference Citation Analysis]